# The Neuroimmune Axis in Gastric Cancer: Bridging Neural Regulation, Tumor Microenvironment, and Immunotherapy

**Authors:** Fangyuan Zhang, Xi Wang, Xinxin Shen, Pei Xiong, Yan Yang, Jincheng Wang

PMC · DOI: 10.32604/or.2025.074893 · Oncology Research · 2026-02-24

## TL;DR

This review explores how the connection between nerves and the immune system influences gastric cancer development and treatment resistance.

## Contribution

It integrates neuroscience and immuno-oncology to propose new therapeutic strategies targeting neural-tumor-immune interactions.

## Key findings

- Neural circuits regulate tumor growth and immune evasion through neurotransmitters and neuropeptides.
- Chronic stress and gut-brain axis signaling enhance immunosuppression in gastric cancer.
- Targeting the neuro-immune axis may improve immunotherapy response rates.

## Abstract

Accumulating evidence indicates that the neuro-immune axis is central to gastric cancer pathogenesis. Dynamic, bidirectional signaling between neural circuits and immune cells promotes tumor progression, shapes an immunosuppressive microenvironment, and contributes to therapeutic resistance. We synthesize current knowledge on how autonomic (sympathetic and parasympathetic) and sensory innervation regulate gastric cancer biology. These circuits act through neurotransmitters (catecholamines, acetylcholine) and neuropeptides (substance P [SP], calcitonin gene-related peptide [CGRP]) to foster tumor growth and angiogenesis, facilitate perineural invasion, and enable immune evasion by recruiting suppressive myeloid and lymphoid populations and by inducing checkpoint molecule expression. We also examine how chronic stress and the microbiota–gut–brain axis intensify immunosuppression via glucocorticoid signaling and microbially derived metabolites. In parallel, we discuss why current immunotherapies achieve only modest response rates (approximately 10%–20%) in many settings, emphasizing neurally mediated mechanisms of resistance. We evaluate therapeutic strategies that target the neuro-immune axis—including pharmacological neuromodulation, selective neural ablation, and rational combination regimens—and outline how single-cell approaches and neural-tumor-microenvironment organoid models can accelerate mechanism-driven translation. This review aims to integrate current evidence from neuroscience and immuno-oncology to construct a conceptual framework for neuro-immune regulation in gastric cancer and to identify potential therapeutic strategies to overcome treatment resistance by targeting neural–tumor–immune crosstalk.

## Linked entities

- **Chemicals:** acetylcholine (PubChem CID 187)
- **Diseases:** gastric cancer (MONDO:0001056)

## Full-text entities

- **Genes:** CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, CAMP (cathelicidin antimicrobial peptide) [NCBI Gene 820] {aka CAP-18, CAP18, CRAMP, FALL-39, FALL39, HSD26}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, CHRNA7 (cholinergic receptor nicotinic alpha 7 subunit) [NCBI Gene 1139] {aka CHRNA7-2, NACHRA7, a7nAChR, nAChR7}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CSF1R (colony stimulating factor 1 receptor) [NCBI Gene 1436] {aka BANDDOS, C-FMS, CD115, CSF-1R, CSFR, FIM2}, VIPR1 (vasoactive intestinal peptide receptor 1) [NCBI Gene 7433] {aka HVR1, II, PACAP-R-2, PACAP-R2, RDC1, V1RG}, TACR1 (tachykinin receptor 1) [NCBI Gene 6869] {aka NK1R, NKIR, SPR, TAC1R}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, NGFR (nerve growth factor receptor) [NCBI Gene 4804] {aka CD271, Gp80-LNGFR, TNFRSF16, p75(NTR), p75NTR}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, TAC1 (tachykinin precursor 1) [NCBI Gene 6863] {aka Hs.2563, NK2, NKNA, NPK, TAC2}, DLG4 (discs large MAGUK scaffold protein 4) [NCBI Gene 1742] {aka MRD62, PSD95, SAP-90, SAP90}, DRD2 (dopamine receptor D2) [NCBI Gene 1813] {aka D2DR, D2R}, DCLK3 (doublecortin like kinase 3) [NCBI Gene 85443] {aka CLR, DCAMKL3, DCDC3C, DCK3}, CagA [NCBI Gene 48200769], CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, NTRK1 (neurotrophic receptor tyrosine kinase 1) [NCBI Gene 4914] {aka MTC, TRK, TRK1, TRKA, Trk-A, p140-TrkA}, VIPR2 (vasoactive intestinal peptide receptor 2) [NCBI Gene 7434] {aka C16DUPq36.3, DUP7q36.3, PACAP-R-3, PACAP-R3, VIP-R-2, VPAC2}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, AKT3 (AKT serine/threonine kinase 3) [NCBI Gene 10000] {aka MPPH, MPPH2, PKB-GAMMA, PKBG, PRKBG, RAC-PK-gamma}, CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 1385] {aka CREB, CREB-1}, DTL (denticleless E3 ubiquitin protein ligase adapter) [NCBI Gene 51514] {aka CDT2, DCAF2, L2DTL, RAMP}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, SYP (synaptophysin) [NCBI Gene 6855] {aka MRX96, MRXSYP, XLID96}, PDCD1 (programmed cell death 1) [NCBI Gene 100533201], LAG3 (lymphocyte activating 3) [NCBI Gene 3902] {aka CD223}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, GABARAP (GABA type A receptor-associated protein) [NCBI Gene 11337] {aka ATG8A, GABARAP-a, MM46}, NPY (neuropeptide Y) [NCBI Gene 4852] {aka PYY4}, Arg1 (arginase, liver) [NCBI Gene 11846] {aka AI, Arg-1, PGIF}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CALCRL (calcitonin receptor like receptor) [NCBI Gene 10203] {aka CGRPR, CRLR, LMPHM8}, CD80 (CD80 molecule) [NCBI Gene 941] {aka B7, B7-1, B7.1, BB1, CD28LG, CD28LG1}, VIP (vasoactive intestinal peptide) [NCBI Gene 7432] {aka PHM27}, NTRK2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 4915] {aka DEE58, EIEE58, GP145-TrkB, OBHD, TRKB, trk-B}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, DRD1 (dopamine receptor D1) [NCBI Gene 1812] {aka D1R, DADR, DRD1A}, ARG1 (arginase 1) [NCBI Gene 383], FOXP3 (forkhead box P3) [NCBI Gene 50943] {aka AIID, DIETER, IPEX, JM2, PIDX, XPID}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, ADRB2 (adrenoceptor beta 2) [NCBI Gene 154] {aka ADRB2R, ADRBR, ARB2, B2AR, BAR, BETA2AR}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, CALCA (calcitonin related polypeptide alpha) [NCBI Gene 796] {aka CALC1, CGRP, CGRP-I, CGRP-alpha, CGRP1, CT}, NR3C1 (nuclear receptor subfamily 3 group C member 1) [NCBI Gene 2908] {aka GCCR, GCR, GCRST, GR, GRL}, FOXP3 (forkhead box P3) [NCBI Gene 444998], IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, ATF2 (activating transcription factor 2) [NCBI Gene 1386] {aka CRE-BP1, CREB-2, CREB2, HB16, TREB7}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, NGF (nerve growth factor) [NCBI Gene 4803] {aka Beta-NGF, HSAN5, NGFB}, TH (tyrosine hydroxylase) [NCBI Gene 7054] {aka DYT14, DYT5b, TYH}
- **Diseases:** neurogenic inflammation (MESH:D020078), gastrointestinal malignancies (MESH:D005770), bile reflux (MESH:D001655), gastric cancer1 (MESH:D013272), chronic (MESH:D002908), neuropathy (MESH:D009422), Tumor-associated macrophages (MESH:D000072716), necrotic (MESH:D009336), migraine (MESH:D008881), brain (MESH:D001927), tumorigenic (MESH:D002471), metastasis (MESH:D009362), neuro (MESH:C536203), cytotoxicity (MESH:D064420), immune dysfunction (MESH:D007154), Infection (MESH:D007239), carcinogenesis (MESH:D063646), gastric adenocarcinoma (MESH:D013274), premalignant lesions (MESH:D009059), visceral pain (MESH:D059265), hypoxia (MESH:D000860), H. pylori infection (MESH:D016481), Pain (MESH:D010146), inflammation (MESH:D007249), collateral injury (MESH:D014947), Neuroinflammation (MESH:D000090862), Neuro-Tumor (MESH:D009369), Dysbiosis (MESH:D064806)
- **Chemicals:** ATP (MESH:D000255), berberine (MESH:D001599), SCFAs (MESH:D005232), Tryptophan (MESH:D014364), dopamine (MESH:D004298), bile acids (MESH:D001647), 2cAMP (-), propranolol (MESH:D011433), Catecholamines (MESH:D002395), Butyrate (MESH:D002087), acetylcholine (MESH:D000109), aprepitant (MESH:D000077608), cyclic adenosine monophosphate (MESH:D000242), glutamate (MESH:D018698), kynurenine (MESH:D007737), GABA (MESH:D005680), Norepinephrine (MESH:D009638), evodiamine (MESH:C049639), ginsenosides (MESH:D036145), epinephrine (MESH:D004837), Cortisol (MESH:D006854)
- **Species:** Homo sapiens (human, species) [taxon 9606], Helicobacter pylori (species) [taxon 210], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12963677/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12963677/full.md

## References

122 references — full list in the complete paper: https://tomesphere.com/paper/PMC12963677/full.md

---
Source: https://tomesphere.com/paper/PMC12963677